LINCOLN, Neb., Feb. 11, 2020 (GLOBE NEWSWIRE) -- National Research Corporation NRC today announced 2019 fourth quarter and year-end financial results.
Fourth quarter 2019 compared to the fourth quarter 2018:
- Total Contract Value increased to $144.8 million, up 10%
- Revenue increased 6% to $32.6 million
- Operating Income increased 27% to $12.0 million
2019 calendar year results compared to 2018:
- Net New Sales of $27.7 million, up 18%
- Revenue increased 7% to $128.0 million
- Operating Income increased 22% to $43.0 million
- Voice of the Customer platform contract value surpassed $100 million, a 31% increase
Commenting on recent performance, Michael D. Hays, chief executive officer of National Research Corporation, said, "Our performance throughout the year reflects strong gains across the continuum of care where we witnessed growth in new customer acquisition and increased spend from existing customers which further validated increasing momentum for NRC's industry-leading Voice of the Customer platform.
Revenue for the quarter ended December 31, 2019, was $32.6 million, compared to $30.6 million for the same quarter in 2018. Net income for the quarter ended December 31, 2019, was $8.7 million, compared to $7.8 million for the quarter ended December 31, 2018. Diluted earnings per share increased to $0.34 for the common stock (formerly Class A) for the quarter ended December 31, 2019, from diluted earnings per share of $0.30 for the quarter ended December 31, 2018.
Regarding the Company's financial performance, Kevin Karas, chief financial officer of National Research Corporation, said, "The significant growth in contract value, combined with the continued shift towards our higher margin VoC platform solutions, translated into strong financial performance with record revenue and operating income in the fourth quarter 2019. On a year-to-date basis, we increased net new sales by 18% over 2018 driven by the compelling value proposition of our VoC platform solutions."
A listen-only simulcast of National Research Corporation's 2019 fourth quarter conference call will be available online at http://edge.media-server.com/mmc/p/c88rjqy6 on February 12, 2020, beginning at 11:00 a.m. Eastern time. The online replay will follow approximately one hour later and continue for 30 days.
For more than 38 years, National Research Corporation has been a leading provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers and other healthcare organizations in the United States and Canada. The Company's solutions enable its clients to understand the voice of the customer with greater clarity, immediacy and depth.
This press release includes "forward-looking" statements related to the Company that can generally be identified as describing the Company's future plans, objectives or goals. Such forward-looking statements are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those currently anticipated. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For further information about the factors that could affect the Company's future results, please see the Company's filings with the Securities and Exchange Commission.
NATIONAL RESEARCH CORPORATION AND SUBSIDIARY
Unaudited Condensed Consolidated Statements of Income
(In thousands, except per share data)
| Three months ended December 31, | Twelve months ended December 31, | ||||||||||||||
| 2019 | 2018 | 2019 | 2018 | ||||||||||||
| Revenue | $ | 32,623 | $ | 30,639 | $ | 127,982 | $ | 119,686 | |||||||
| Operating expenses: | |||||||||||||||
| Direct expenses | 11,166 | 11,892 | 46,435 | 47,577 | |||||||||||
| Selling, general and administrative | 8,241 | 7,885 | 32,973 | 31,371 | |||||||||||
| Depreciation and amortization | 1,254 | 1,467 | 5,539 | 5,463 | |||||||||||
| Total operating expenses | 20,661 | 21,244 | 84,947 | 84,411 | |||||||||||
| Operating income | 11,962 | 9,395 | 43,035 | 35,275 | |||||||||||
| Other income (expense): | |||||||||||||||
| Interest income | 13 | 6 | 37 | 62 | |||||||||||
| Interest expense | (478 | ) | (522 | ) | (2,091 | ) | (1,513 | ) | |||||||
| Other, net | (132 | ) | 661 | (462 | ) | 885 | |||||||||
| Total other income (expense) | (597 | ) | 145 | (2,516 | ) | (566 | ) | ||||||||
| Income before income taxes | 11,365 | 9,540 | 40,519 | 34,709 | |||||||||||
| Provision for income taxes | 2,667 | 1,739 | 8,113 | 4,662 | |||||||||||
| Net income | $ | 8,698 | $ | 7,801 | $ | 32,406 | $ | 30,047 | |||||||
| Earnings per share of common stock: | |||||||||||||||
| Basic earnings per share: | |||||||||||||||
| Common (formerly Class A) | $ | 0.35 | $ | 0.32 | $ | 1.30 | $ | 1.08 | |||||||
| Class B | $ | -- | $ | -- | $ | -- | $ | 1.31 | |||||||
| Diluted earnings per share: | |||||||||||||||
| Common (formerly Class A) | $ | 0.34 | $ | 0.30 | $ | 1.26 | $ | 1.04 | |||||||
| Class B | $ | -- | $ | -- | $ | -- | $ | 1.27 | |||||||
| Weighted average shares and share equivalents outstanding | |||||||||||||||
| Common (formerly Class A) - basic | 24,852 | 24,684 | 24,809 | 23,562 | |||||||||||
| Class B - basic | -- | -- | -- | 3,527 | |||||||||||
| Common (formerly Class A) - diluted | 25,715 | 25,534 | 25,652 | 24,448 | |||||||||||
| Class B - diluted | -- | -- | -- | 3,628 | |||||||||||
NATIONAL RESEARCH CORPORATION AND SUBSIDIARY
Unaudited Condensed Consolidated Balance Sheets
(Dollars in thousands, except per share amounts and par value)
| December 31, 2019 | December 31, 2018 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 13,517 | $ | 12,991 | ||||
| Accounts receivable, net | 11,639 | 11,922 | ||||||
| Income taxes receivable | 69 | 348 | ||||||
| Other current assets | 3,932 | 3,149 | ||||||
| Total current assets | 29,157 | 28,410 | ||||||
| Net property and equipment | 13,530 | 14,153 | ||||||
| Goodwill | 57,935 | 57,831 | ||||||
| Other, net | 10,063 | 7,638 | ||||||
| Total assets | $ | 110,685 | $ | 108,032 | ||||
| Liabilities and Shareholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Notes payable and line of credit | $ | 4,378 | $ | 3,667 | ||||
| Accounts payable and accrued expenses | 4,913 | 3,447 | ||||||
| Accrued compensation | 6,086 | 5,798 | ||||||
| Income taxes payable | 366 | 636 | ||||||
| Dividends payable | 5,239 | 17,113 | ||||||
| Deferred revenue | 16,648 | 16,244 | ||||||
| Other current liabilities | 525 | 204 | ||||||
| Total current liabilities | 38,155 | 47,109 | ||||||
| Notes payable, net of current portion | 29,795 | 34,176 | ||||||
| Other non-current liabilities | 9,843 | 7,664 | ||||||
| Total liabilities | 77,793 | 88,949 | ||||||
| Shareholders' equity: | ||||||||
| Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued | -- | -- | ||||||
| Common stock, $0.001 par value; authorized 60,000,000 shares, issued 30,151,574 in 2019 and 29,917,667 in 2018, outstanding 24,947,500 in 2019 and 24,800,796 in 2018 | 30 | 30 | ||||||
| Additional paid-in capital | 162,154 | 157,312 | ||||||
| Retained earnings (accumulated deficit) | (93,357 | ) | (106,339 | ) | ||||
| Accumulated other comprehensive loss, foreign currency translation adjustment | (2,209 | ) | (2,916 | ) | ||||
| Treasury stock | (33,726 | ) | (29,004 | ) | ||||
| Total shareholders' equity | 32,892 | 19,083 | ||||||
| Total liabilities and shareholders' equity | $ | 110,685 | $ | 108,032 | ||||
| Contact: | Kevin R. Karas Chief Financial Officer 402-475-2525 |
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
